Global cancer statistics
TL;DR: A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination, and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake.
read more
Abstract: The global burden of cancer continues to increase largely because of the aging and growth of the world population alongside an increasing adoption of cancer-causing behaviors, particularly smoking, in economically developing countries. Based on the GLOBOCAN 2008 estimates, about 12.7 million cancer cases and 7.6 million cancer deaths are estimated to have occurred in 2008; of these, 56% of the cases and 64% of the deaths occurred in the economically developing world. Breast cancer is the most frequently diagnosed cancer and the leading cause of cancer death among females, accounting for 23% of the total cancer cases and 14% of the cancer deaths. Lung cancer is the leading cancer site in males, comprising 17% of the total new cancer cases and 23% of the total cancer deaths. Breast cancer is now also the leading cause of cancer death among females in economically developing countries, a shift from the previous decade during which the most common cause of cancer death was cervical cancer. Further, the mortality burden for lung cancer among females in developing countries is as high as the burden for cervical cancer, with each accounting for 11% of the total female cancer deaths. Although overall cancer incidence rates in the developing world are half those seen in the developed world in both sexes, the overall cancer mortality rates are generally similar. Cancer survival tends to be poorer in developing countries, most likely because of a combination of a late stage at diagnosis and limited access to timely and standard treatment. A substantial proportion of the worldwide burden of cancer could be prevented through the application of existing cancer control knowledge and by implementing programs for tobacco control, vaccination (for liver and cervical cancers), and early detection and treatment, as well as public health campaigns promoting physical activity and a healthier dietary intake. Clinicians, public health professionals, and policy makers can play an active role in accelerating the application of such interventions globally.
read more
Chat with Paper
AI Agents for this Paper
Find similar papers on Google Scholar, PubMed and Arxiv
Write a critical review of this paper
Analyze citations of this paper to find unaddressed research gaps
Citations
Rituximab in B-Cell Hematologic Malignancies: A Review of 20 Years of Clinical Experience
Gilles Salles,Martin Barrett,Robin Foà,Joerg Maurer,Susan O'Brien,Nancy Valente,Michael Wenger,David G. Maloney +7 more
TL;DR: The preclinical development of rituximab and the clinical experience gained in the treatment of hematologic B-cell malignancies are reviewed, with a focus on the well-established intravenous route of administration.
520
Initial results from a prospective cohort study of 5583 cases of thyroid carcinoma treated in the United States during 1996: An American college of surgeons commission on cancer patient care evaluation study
Scott A. Hundahl,Blake Cady,Myles P. Cunningham,Ernest L. Mazzaferri,Rosemary F. McKee,Juan Rosai,Jatin P. Shah,Amy Fremgen,Andrew K. Stewart,Simon Hölzer +9 more
TL;DR: In this article, a prospective cohort study of U.S. thyroid carcinoma cases treated in 1996 was conducted and the most frequently used diagnostic modalities were fine needle aspiration of the thyroid gland (53%), thyroid lymph node (7%), thyroid nuclear scan (39%), and ultrasound (38%).
Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment.
Sara I. Pai,William H. Westra +1 more
TL;DR: A more complete understanding of the molecular genetics of head and neck cancer is providing new insights into long-held but poorly comprehended concepts such as field cancerization and is introducing various biomarkers with potential application for diagnosing, staging, monitoring, and prognosticating HNSCC.
Ultra-fast, label-free isolation of circulating tumor cells from blood using spiral microfluidics
Majid Ebrahimi Warkiani,Majid Ebrahimi Warkiani,Bee Luan Khoo,Bee Luan Khoo,Lidan Wu,Andy Tay,Andy Tay,Ali Asgar S. Bhagat,Jongyoon Han,Jongyoon Han,Chwee Teck Lim,Chwee Teck Lim +11 more
TL;DR: This protocol describes detailed procedures for the production and use of a label-free spiral microfluidic device to allow size-based isolation of viable CTCs using hydrodynamic forces that are present in curvilinear microchannels.
519
Genome-scale analysis of DNA methylation in lung adenocarcinoma and integration with mRNA expression
Suhaida A. Selamat,Brian Chung,Luc Girard,Wei Zhang,Ying Zhang,Mihaela Campan,Kimberly D. Siegmund,Michael Koss,Jeffrey A. Hagen,Wan L. Lam,Stephen Lam,Adi F. Gazdar,Ite A. Laird-Offringa +12 more
TL;DR: In this paper, the authors performed genome-scale DNA methylation profiling using the Illumina Infinium HumanMethylation27 platform on 59 matched lung adenocarcinoma/non-tumor lung pairs.
References
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008.
TL;DR: The results for 20 world regions are presented, summarizing the global patterns for the eight most common cancers, and striking differences in the patterns of cancer from region to region are observed.
22.9K
IARC Monographs on the Evaluation of Carcinogenic Risks to Humans
TL;DR: This timely monograph is a distillation of knowledge of hepatitis B, C and D, based on a review of 1000 studies by a small group of scientists, and it is concluded that hepatitis D virus cannot be classified as a human carcinogen.
11.5K
•Book
International Classification of Diseases for Oncology
Constance L. Percy,Valerie Van Holten,Calum S. Muir +2 more
- 01 Jun 1990
TL;DR: This list of diseases for oncology includes cancers of the central nervous system, as well as other types of diseases such as lymphoma, leukaemia, and so on.
4.2K
Screening and Prostate-Cancer Mortality in a Randomized European Study
Fritz H. Schröder,Jonas Hugosson,Monique J. Roobol,Stefano Ciatto,Vera Nelen,Maciej Kwiatkowski,Marcos Lujan,Hans Lilja,Marco Zappa,Louis Denis,Franz Recker,A. Berenguer,Liisa Määttänen,Chris H. Bangma,Gunnar Aus,Arnauld Villers,Xavier Rebillard,Theodorus van der Kwast,Bert G. Blijenberg,Sue Moss,Harry J. de Koning,Anssi Auvinen +21 more
TL;DR: PSA-based screening reduced the rate of death from prostate cancer by 20% but was associated with a high risk of overdiagnosis.
International Classification of Diseases for Oncology
TL;DR: Use ofImmunofluorescence in the Diagnosis of Virus Infections using audio-tape slide programme and slides and cassette by P. S. Gardner.
3.5K